 Complement Inactivating Agents
"Complement Inactivating Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.
| Descriptor ID |
D051056
|
| MeSH Number(s) |
D27.505.696.477.656.500
|
| Concept/Terms |
Complement Inactivating Agents- Complement Inactivating Agents
- Agents, Complement Inactivating
- Inactivating Agents, Complement
- Complement Inhibitors
- Inhibitors, Complement
- Complement Inhibiting Agents
- Agents, Complement Inhibiting
- Inhibiting Agents, Complement
|
Below are MeSH descriptors whose meaning is more general than "Complement Inactivating Agents".
Below are MeSH descriptors whose meaning is more specific than "Complement Inactivating Agents".
This graph shows the total number of publications written about "Complement Inactivating Agents" by people in this website by year, and whether "Complement Inactivating Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2016 | 3 | 0 | 3 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 3 | 2 | 5 | | 2021 | 1 | 2 | 3 | | 2023 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement Inactivating Agents" by people in Profiles.
-
Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024 May; 39(5):1387-1404.
-
Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, Gasteyger C, Java A, Leguizamo J, Lloyd-Price L, Pham TP, Symonds T, Tomazos I, Wang Y. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023 09; 12(9):e230036.
-
Pittock SJ, Barnett M, Bennett JL, Berthele A, de S?ze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol. 2023 06; 93(6):1053-1068.
-
Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol. 2022 03; 37(3):521-535.
-
Gadwa J, Bickett TE, Darragh LB, Knitz MW, Bhatia S, Piper M, Van Court B, Bhuvane S, Nguyen D, Nangia V, Kleczko EK, Nemenoff RA, Karam SD. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer. J Immunother Cancer. 2021 03; 9(3).
-
Li C, Patel K, Tu Z, Yang X, Kulik L, Alawieh A, Allen P, Cheng Q, Wallace C, Kilkenny J, Kwon J, Gibney B, Cantu E, Sharma A, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, Atkinson C. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
-
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na?ve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237.
-
Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Mol Immunol. 2020 12; 128:175-187.
-
Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol. 2020 12; 221:108616.
-
Gaikwad H, Li Y, Gifford G, Groman E, Banda NK, Saba L, Scheinman R, Wang G, Simberg D. Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood. Bioconjug Chem. 2020 07 15; 31(7):1844-1856.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|